AtaiBeckley Trial Shows Promise for Short-Acting Psychedelic Depression Treatment
Published in JAMA, the phase 2b trial found that a single dose of the psychedelic compound 5-MeO-DMT significantly reduced depressive ...
Published in JAMA, the phase 2b trial found that a single dose of the psychedelic compound 5-MeO-DMT significantly reduced depressive ...
Entropy Neurodynamics, GH Research and Helus Pharma are taking different approaches to a shared challenge: developing psychedelic medicines that can ...
Few stories in modern drug development begin with an anonymous underground pamphlet, a manual typewriter and a desert toad. Yet ...
When Eli Lilly agreed to acquire Atai Beckley in a deal worth up to US$3.8 billion, it wasn't simply the ...
Global pharmaceutical giant Eli Lilly is reportedly in advanced discussions to acquire psychedelic drug developer AtaiBeckley, in what would become ...
Psychedelics.media delivers trusted news, intelligence, and insights for the global psychedelic medicine industry.
